When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?

被引:20
作者
Cerfolio, Robert James
Bryant, Ayesha S.
机构
[1] Univ Alabama Birmingham, Div Cardiothorac Surg, Dept Surg, Sch Publ Hlth, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA
关键词
D O I
10.1016/j.athoracsur.2007.05.050
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The ideal time to repeat a 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography ( PET)/computed tomography (CT) scan to accurately restage a patient after neoadjuvant chemoradiotherapy for non-small cell lung cancer (NSCLC) is unknown. Methods. This retrospective cohort study used a prospective database of patients who underwent neoadjuvant chemoradiotherapy, an initial and repeat FDG-PET/ CT scan, and pathologic staging. The accuracy of the clinical stage suggested by repeat FDG-PET/ CT was compared with the actual pathologic stage. Receiver operating characteristic (ROC) curves were used to determine when it was most accurate to repeat the FDG-PET/ CT after the completion of the last dose of chest radiation. Results. The study comprised 109 patients, 93 of whom patients received 60 Gy ( or higher) of radiotherapy. The median time to restaging was 24 days ( range, 2 to 88 days). ROC analysis showed the optimal time to restage patients was 26 days for overall staging ( area under the curve [AUC], 0.88) and 29 days for N2 restaging ( AUC, 0.82). The accuracy for overall stage was 3 (38%) of 8 for patients for less than 10 days, 28 (72%) of 39 for patients between 11 and 20 days, 42 (88%) of 49 between 21 and 30 days, and 8 (62%) of 13 for 31 days or more. The accuracy for these time intervals for the restaging of the N2 lymph node was 50% (1/2) 40% (2/5), 88% (7/8), and 100% (3/3), respectively. Conclusions. The optimal time to perform a repeat FDG-PET/ CT scan after the completion of neoadjuvant chemotherapy and high-dose radiotherapy to maximize its accuracy for restaging patients with NSCLC is about 1 month after the last dose of radiation.
引用
收藏
页码:1092 / 1097
页数:6
相关论文
共 24 条
[1]   Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration [J].
Aquino, SL ;
Asmuth, JC ;
Alpert, NM ;
Halpern, EF ;
Fischman, AJ .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2003, 27 (04) :479-484
[2]  
BECK JR, 1986, ARCH PATHOL LAB MED, V110, P685
[3]   Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer [J].
Bryant, Ayesha S. ;
Cerfolio, Robert J. ;
Klemm, Katrin M. ;
Ojha, Buddhiwardhan .
ANNALS OF THORACIC SURGERY, 2006, 82 (02) :417-423
[4]  
BULZEBRUCK H, 1992, CANCER-AM CANCER SOC, V70, P1102, DOI 10.1002/1097-0142(19920901)70:5<1102::AID-CNCR2820700514>3.0.CO
[5]  
2-5
[6]   Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer [J].
Cerfolio, RJ ;
Bryant, AS ;
Winokur, TS ;
Ohja, B ;
Bartolucci, AA .
ANNALS OF THORACIC SURGERY, 2004, 78 (06) :1903-1909
[7]   Improving the inaccuracies of clinical staging of patients with NSCLC: A prospective trial [J].
Cerfolio, RJ ;
Bryant, AS ;
Ojha, B ;
Eloubeidi, M .
ANNALS OF THORACIC SURGERY, 2005, 80 (04) :1207-1214
[8]   Pulmonary resection after high-dose and low-dose chest irradiation [J].
Cerfolio, RJ ;
Bryant, AS ;
Spencer, SA ;
Bartolucci, AA .
ANNALS OF THORACIC SURGERY, 2005, 80 (04) :1224-1230
[9]   Intercostal muscle flap to buttress the bronchus at risk and the thoracic esophageal-gastric anastomosis [J].
Cerfolio, RJ ;
Bryant, AS ;
Yamamuro, M .
ANNALS OF THORACIC SURGERY, 2005, 80 (03) :1017-1020
[10]   The role of FDG-PET scan in staging patients with nonsmall cell carcinoma [J].
Cerfolio, RJ ;
Ojha, B ;
Bryant, AS ;
Bass, CS ;
Bartalucci, AA ;
Mountz, JM .
ANNALS OF THORACIC SURGERY, 2003, 76 (03) :861-866